Yao B, Zhu L, Jiang Q, Xia HA. Safety monitoring in clinical trials. Pharmaceutics. 2013;5(1):94–106.

Sartor O, Halabi S, editors. Independent data monitoring committees: an update and overview. Urologic oncology: seminars and original investigations. Elsevier; 2015.

DeMets DL, Wittes J. Data monitoring committee interim reports: we must get there soon! Clin Trails. 2022;19(1):107–11.

Evans SR, Bigelow R, Chuang-Stein C, Ellenberg SS, Gallo P, He W, Jiang Q, Rockhold F. Presenting risks and benefits: helping the data monitoring committee do its job. Ann Intern Med. 2020;172(2):119–25.

FDA. Establishment and operation of clinical trial data monitoring committees. Food Drug Administration Maryland; 2006.

DeMets DL. Futility approaches to interim monitoring by data monitoring committees. Clin Trails. 2006;3(6):522–9.

Sashegyi A. A benefit-risk model to facilitate DMC-sponsor communication and decision making. Drug Inform Journal: DIJ/Drug Inform Association. 2011;45(6):749–57.

FDA. Benefit-risk assessment for new drug and biological products. Food Drug Administration Maryland; 2021.

Vandemeulebroecke M, Baillie M, Mirshani A, Lesaffre E. DMC reports in the 21st century: towards better tools for decision-making. Trials. 2023;24(1):289.

Lynd LD, O’brien BJ. Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. J Clin Epidemiol. 2004;57(8):795–803.

Shaffer ML, Watterberg KL. Joint distribution approaches to simultaneously quantifying benefit and risk. BMC Med Res Methodol. 2006;6(1):1–8.

Chuang-Stein C, Mohberg NR, Sinkula MS. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Stat Med. 1991;10(9):1349–59.

Cui S, Zhao Y, Tiwari RC. Bayesian approach to personalized benefit-risk assessment. Stat Biopharm Res. 2016;8(3):316–24.

Pritchett YL, Tamura R. Global benefit–risk assessment in designing clinical trials and some statistical considerations of the method. Pharm Statistics: J Appl Stat Pharm Ind. 2008;7(3):170–8.

Yan D, Ahn C, Azadeh S, Atlas M, Tiwari R. A bayesian approach to benefit–risk assessment in clinical studies with longitudinal data. J Biopharm Stat. 2020;30(3):574–91.

Zhao Y, Zalkikar J, Tiwari RC, LaVange LM. A bayesian approach for benefit-risk assessment. Stat Biopharm Res. 2014;6(4):326–37.

Mussen F, Salek S, Walker S. A quantitative approach to benefit-risk assessment of medicines–part 1: the development of a new model using multi‐criteria decision analysis. Pharmacoepidemiol Drug Saf. 2007;16(S1):S2–15.

Menzies T, Saint-Hilary G, Mozgunov P. A comparison of various aggregation functions in multi-criteria decision analysis for drug benefit–risk assessment. Stat Methods Med Res. 2022;31(5):899–916.

Waddingham E, Mt-Isa S, Nixon R, Ashby D. A bayesian approach to probabilistic sensitivity analysis in structured benefit‐risk assessment. Biom J. 2016;58(1):28–42.

Tervonen T, Van Valkenhoef G, Buskens E, Hillege HL, Postmus D. A stochastic multicriteria model for evidence-based decision making in drug benefit‐risk analysis. Stat Med. 2011;30(12):1419–28.

Leening MJG, Mahmoud KD. Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology. Eur J Epidemiol. 2021;36(11):1103–9. https://doi.org/10.1007/s10654-021-00820-x.

Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888–98. https://doi.org/10.1001/jama.2022.5368s.

Mussen F, Salek S, Walker S. A quantitative approach to benefit-risk assessment of medicines – part 1: the development of a new model using multi-criteria decision analysis. Pharmacoepidemiol Drug Saf. 2007;16(S1):S2–15.

National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v6.0. cancer therapy evaluation program (CTEP). Anticipated publication date: Fall 2022; 2022. Retrieved from https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50